<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947100</url>
  </required_header>
  <id_info>
    <org_study_id>RM002</org_study_id>
    <secondary_id>P20GM109021</secondary_id>
    <nct_id>NCT02947100</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Sickle Cell Disease</brief_title>
  <official_title>Phase I/II Safety and Dose Escalation Trial of the Omega-3 Fatty Acids Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in Children and Young Adults With Sickle Cell Disease (SCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robin E. Miller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solutex GC, S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nemours Children's Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of a new formulation of the omega-3
      fatty acids Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) and to assess whether
      it decreases inflammation and inflammatory pain in children and young adults with Sickle Cell
      Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical safety, in a dose escalation trial of SCD-Omegatex™ as evidenced by an absence of adverse events.</measure>
    <time_frame>6 months with continuous monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine whether 6 months of supplementation with SCD-Omegatex™ will reduce thermal sensitivity by Quantitative Sensory Testing to below pre-treatment levels</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-associated Quality of Life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with pain measured by iPad daily report pain calendar</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in individual thermal sensitivity thresholds by QST</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Thrombin generation as assessed by Calibrated Automated Thrombogram</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>high sensitivity C-reactive protein (mg/L)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma lipidomic analysis</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>urine Resolvin D1 (pg/mg creatinine)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma levels of lactate dehydrogenase (IU/L)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>fetal hemoglobin (%)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>analysis of pro and anti-inflammatory cytokines in plasma including interleukin (IL)1-beta, IL-4, IL-6, IL-8, IL-10 and tumor necrosis factor (TNF) alpha ( pg/ml)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma Endothelin-1(pg/ml)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma levels soluble vascular adhesion molecule -1 (VCAM-1) (ng/ml)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma levels of soluble P-selectin (ng/ml)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>plasma levels of soluble L-selectin (ng/ml)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>hemostatic markers in plasma including d-dimers and prothrombin fragment 1.2 (nmol/L)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>SCD-Omegatex™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-Omegatex™</intervention_name>
    <description>Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a &quot;3+3&quot; design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose.</description>
    <arm_group_label>SCD-Omegatex™</arm_group_label>
    <other_name>Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who meet all of the following criteria are eligible for enrollment into the study:

          -  Participant has signed the informed consent/assent with parent signing informed
             consent as age appropriate.

          -  Established diagnosis of HbSS, HbSC or HbSβo Thalassemia

          -  History of ≥1 vasoocclusive events (managed at home and/or in hospital) in preceding
             12 months.

          -  Regular compliance with comprehensive care.

          -  Aged 8 years or greater and less than 26 years.

          -  At enrollment, subject should be in his/her baseline steady state and not in the midst
             of any acute complication due to SCD. Must be at least 2 weeks from infection or
             vasoocclusive crisis at time of screening labs

        Exclusion Criteria:

          -  Baseline hemoglobin levels &lt;5.5 gm/dL.

          -  Inability to swallow capsules

          -  Poor compliance with previous treatment regimens.

          -  Hepatic dysfunction

          -  Renal dysfunction

          -  PT and/or PTT ≥ 20% outside of normal

          -  Allergy to fish, shell fish or soy

          -  Triglyceride levels &lt;80mg/dL.

          -  Pregnancy.

          -  Chronic Transfusion Therapy.

          -  Transfusion within the last 30 days.

          -  Treatment with any investigational drug or regular fish oil supplementations in last
             60 days.

          -  Currently receiving another investigational agent, or on such an agent with the last
             60 days.

          -  Dosage changes in preceding 3 months if on hydroxyurea

          -  Diagnosed bleeding disorder or patient on concomitant anti-coagulation.

          -  Conditional or abnormal result on most recent transcranial doppler or history of
             stroke.

          -  Other active chronic illness that could adversely affect subjects performance

          -  Children in Care

          -  Platelet count less than 100,000
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin E Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemours Children's Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin E Miller, MD</last_name>
    <phone>302-651-5500</phone>
    <email>rmiller@nemours.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn S Brown, FNP, CCRC</last_name>
    <phone>302-298-7411</phone>
    <email>DawnS.Brown@nemours.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nemours/Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19899</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin E Miller, MD</last_name>
      <phone>302-651-5500</phone>
      <email>rmiller@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Dawn S Brown, FNP, CCRC</last_name>
      <phone>302-298-7411</phone>
      <email>DawnS.Brown@nemours.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Daak AA, Ghebremeskel K, Hassan Z, Attallah B, Azan HH, Elbashir MI, Crawford M. Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2013 Jan;97(1):37-44. doi: 10.3945/ajcn.112.036319. Epub 2012 Nov 28.</citation>
    <PMID>23193009</PMID>
  </reference>
  <reference>
    <citation>Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-37. Review.</citation>
    <PMID>17090225</PMID>
  </reference>
  <reference>
    <citation>Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015 Apr;1851(4):469-84. doi: 10.1016/j.bbalip.2014.08.010. Epub 2014 Aug 20. Review.</citation>
    <PMID>25149823</PMID>
  </reference>
  <reference>
    <citation>Tomer A, Kasey S, Connor WE, Clark S, Harker LA, Eckman JR. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. Thromb Haemost. 2001 Jun;85(6):966-74.</citation>
    <PMID>11434703</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nemours Children's Clinic</investigator_affiliation>
    <investigator_full_name>Robin E. Miller</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>Docosahexaenoic Acid (DHA)</keyword>
  <keyword>Eicosapentaenoic Acid (EPA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

